triazolam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diazepam derivatives	2729	28911-01-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: triazolam U-33,030 U 33,030 U33,030	A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Molecular weight: 343.21 Formula: C17H12Cl2N4 CLOGP: 2.62 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 43.07 ALOGS: -4.27 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

triazolam
U-33,030
U 33,030
U33,030

A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.

Molecular weight: 343.21
Formula: C17H12Cl2N4
CLOGP: 2.62
LIPINSKI: 0
HAC: 4
HDO: 0
TPSA: 43.07
ALOGS: -4.27
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.25	mg	O
0.20	mg	SL

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.05 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.02 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	44 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.58 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.10 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.70 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 15, 1982	FDA	PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sopor	697.70	15.46	219	9579	21945	63457279
Drug abuse	421.89	15.46	211	9587	72307	63406917
Overdose	217.19	15.46	163	9635	114915	63364309
Intentional self-injury	192.24	15.46	89	9709	25598	63453626
Suicide attempt	177.93	15.46	113	9685	60805	63418419
Intentional overdose	122.14	15.46	97	9701	74055	63405169
Loss of consciousness	93.96	15.46	103	9695	118018	63361206
Coma	82.74	15.46	73	9725	64291	63414933
Altered state of consciousness	76.56	15.46	48	9750	25182	63454042
Hepatic function abnormal	75.23	15.46	55	9743	37087	63442137
Depressed level of consciousness	57.96	15.46	59	9739	62019	63417205
Corneal epithelium defect	47.48	15.46	11	9787	341	63478883
Alcohol interaction	44.58	15.46	16	9782	2393	63476831
Somnolence	43.05	15.46	89	9709	178596	63300628
Toxicity to various agents	42.77	15.46	108	9690	247142	63232082
Anterior chamber cell	42.72	15.46	11	9787	533	63478691
Blood creatine phosphokinase increased	42.07	15.46	36	9762	30394	63448830
Punctate keratitis	41.28	15.46	11	9787	610	63478614
Completed suicide	36.78	15.46	74	9724	145599	63333625
Bradyphrenia	36.63	15.46	19	9779	6961	63472263
Joint swelling	34.10	15.46	5	9793	327661	63151563
Purpura senile	32.85	15.46	9	9789	554	63478670
Bradykinesia	32.73	15.46	16	9782	5172	63474052
Neuroleptic malignant syndrome	31.78	15.46	21	9777	12035	63467189
Corneal oedema	31.76	15.46	11	9787	1482	63477742
Drug interaction	31.49	15.46	92	9706	229039	63250185
Drug intolerance	31.46	15.46	5	9793	308656	63170568
Application site injury	29.77	15.46	5	9793	26	63479198
Hyponatraemic encephalopathy	29.28	15.46	7	9791	249	63478975
Liver disorder	28.21	15.46	38	9760	53649	63425575
Tarsal tunnel syndrome	28.12	15.46	8	9790	566	63478658
Peripheral swelling	27.80	15.46	4	9794	265938	63213286
Hypersensitivity	27.14	15.46	6	9792	292679	63186545
Fatigue	26.97	15.46	61	9737	887967	62591257
Hyporesponsive to stimuli	26.88	15.46	9	9789	1095	63478129
Hypokinesia	26.77	15.46	20	9778	13916	63465308
Drug ineffective	26.23	15.46	79	9719	1044686	62434538
Blood lactate dehydrogenase increased	25.34	15.46	24	9774	23092	63456132
Swelling	24.82	15.46	6	9792	275372	63203852
Delusion	24.78	15.46	18	9780	11999	63467225
Dependence	24.73	15.46	10	9788	2067	63477157
Vestibular disorder	24.59	15.46	9	9789	1422	63477802
Serotonin syndrome	24.48	15.46	26	9772	28656	63450568
Drug dependence	24.17	15.46	24	9774	24459	63454765
Postoperative delirium	24.07	15.46	5	9793	92	63479132
Application site ulcer	23.68	15.46	5	9793	100	63479124
Syncope	23.16	15.46	54	9744	117331	63361893
Intentional product misuse	23.13	15.46	37	9761	60880	63418344
Labelled drug-drug interaction issue	22.99	15.46	8	9790	1093	63478131
Infusion related reaction	22.82	15.46	5	9793	245516	63233708
Blood alkaline phosphatase increased	21.94	15.46	30	9768	42937	63436287
Resorption bone increased	21.85	15.46	8	9790	1266	63477958
Treatment failure	20.78	15.46	3	9795	199040	63280184
Interstitial lung disease	20.03	15.46	35	9763	61873	63417351
Rhabdomyolysis	19.94	15.46	29	9769	43922	63435302
Electrocardiogram T wave inversion	19.78	15.46	10	9788	3471	63475753
Delirium	19.60	15.46	31	9767	50510	63428714
Arthropathy	19.49	15.46	6	9792	234786	63244438
Hyperventilation	19.46	15.46	12	9786	6104	63473120
Aspartate aminotransferase increased	19.44	15.46	43	9755	90234	63388990
Product dose omission issue	19.43	15.46	6	9792	234307	63244917
Intellectual disability	19.30	15.46	7	9791	1079	63478145
Hallucination, visual	19.20	15.46	19	9779	19279	63459945
Torsade de pointes	18.87	15.46	16	9782	13335	63465889
Restlessness	18.86	15.46	23	9775	29430	63449794
Sinusitis	18.44	15.46	6	9792	226647	63252577
Electrocardiogram QT prolonged	18.41	15.46	33	9765	59497	63419727
Agitation	18.32	15.46	33	9765	59724	63419500
Arthralgia	18.17	15.46	38	9760	569672	62909552
Attention deficit hyperactivity disorder	17.96	15.46	9	9789	3067	63476157
Pain	17.81	15.46	57	9741	740571	62738653
Drug eruption	17.71	15.46	22	9776	28672	63450552
Abnormal behaviour	17.54	15.46	19	9779	21407	63457817
Cerebral infarction	17.52	15.46	20	9778	23873	63455351
Alopecia	17.27	15.46	16	9782	337520	63141704
Speech disorder	17.27	15.46	26	9772	40603	63438621
Blepharospasm	17.16	15.46	11	9787	5985	63473239
Rheumatoid arthritis	16.98	15.46	9	9789	253810	63225414
Poisoning	16.51	15.46	15	9783	13685	63465539
Hypoglycaemic coma	16.42	15.46	8	9790	2567	63476657
Salivary gland cancer stage IV	16.14	15.46	3	9795	30	63479194
Extrasystoles	16.10	15.46	10	9788	5150	63474074
Product use issue	16	15.46	7	9791	220513	63258711
Pulse absent	15.73	15.46	10	9788	5364	63473860
Infection	15.52	15.46	8	9790	229165	63250059

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sopor	304.47	15.43	110	7438	12026	34937357
Drug abuse	143.42	15.43	139	7409	98957	34850426
Intentional overdose	94.43	15.43	77	7471	43597	34905786
Suicide attempt	76.30	15.43	65	7483	39051	34910332
Depressed level of consciousness	75.13	15.43	67	7481	42774	34906609
Blood creatine phosphokinase increased	61.12	15.43	61	7487	44796	34904587
Overdose	53.59	15.43	81	7467	90978	34858405
Alcohol interaction	53.33	15.43	21	7527	2892	34946491
Bradyphrenia	46.29	15.43	22	7526	4776	34944607
Intentional self-injury	44.70	15.43	31	7517	13740	34935643
Altered state of consciousness	42.49	15.43	37	7511	22856	34926527
Neuroleptic malignant syndrome	41.64	15.43	33	7515	17901	34931482
Somnolence	40.54	15.43	80	7468	111036	34838347
Completed suicide	39.90	15.43	74	7474	98094	34851289
Hepatic function abnormal	39.04	15.43	48	7500	44315	34905068
Loss of consciousness	35.71	15.43	64	7484	82603	34866780
Reduced facial expression	35.41	15.43	12	7536	1079	34948304
Interstitial lung disease	31.39	15.43	53	7495	65229	34884154
Road traffic accident	29.98	15.43	27	7521	17423	34931960
Eye haematoma	29.84	15.43	6	7542	65	34949318
Drug dependence	29.45	15.43	31	7517	24186	34925197
Gamma-glutamyltransferase increased	26.30	15.43	32	7516	29199	34920184
Dissociative disorder	22.76	15.43	7	7541	462	34948921
Suicidal ideation	22.40	15.43	35	7513	40353	34909030
Liver disorder	21.75	15.43	31	7517	32966	34916417
Off label use	21.56	15.43	36	7512	419488	34529895
Rhabdomyolysis	21.20	15.43	46	7502	68117	34881266
Decreased appetite	20.91	15.43	81	7467	166311	34783072
Blood lactate dehydrogenase increased	20.41	15.43	25	7523	22965	34926418
Hypokinesia	19.88	15.43	16	7532	8864	34940519
Delirium	18.90	15.43	34	7514	43957	34905426
Hypothermia	17.22	15.43	16	7532	10732	34938651
Dissociation	17.22	15.43	8	7540	1650	34947733
Alanine aminotransferase increased	17.08	15.43	47	7501	80768	34868615
Hyporesponsive to stimuli	16.88	15.43	7	7541	1101	34948282
Disseminated intravascular coagulation	16.64	15.43	22	7526	21794	34927589
Fatigue	16.22	15.43	35	7513	370618	34578765
Toxicity to various agents	15.79	15.43	85	7463	200277	34749106

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sopor	927.49	14.86	316	15059	32694	79696319
Drug abuse	507.18	14.86	341	15034	162350	79566663
Suicide attempt	248.62	14.86	170	15205	82762	79646251
Intentional self-injury	226.55	14.86	115	15260	32304	79696709
Overdose	216	14.86	219	15156	183987	79545026
Intentional overdose	202.89	14.86	166	15209	105794	79623219
Depressed level of consciousness	122.47	14.86	120	15255	96532	79632481
Loss of consciousness	114.34	14.86	151	15224	167792	79561221
Alcohol interaction	88.99	14.86	34	15341	4840	79724173
Somnolence	88.20	14.86	162	15213	238819	79490194
Hepatic function abnormal	85.61	14.86	87	15288	73020	79655993
Blood creatine phosphokinase increased	85.44	14.86	83	15292	66007	79663006
Altered state of consciousness	78.23	14.86	66	15309	43756	79685257
Bradyphrenia	72.11	14.86	37	15338	10603	79718410
Coma	66.12	14.86	89	15286	100560	79628453
Neuroleptic malignant syndrome	60.83	14.86	47	15328	27512	79701501
Completed suicide	60.43	14.86	141	15234	245626	79483387
Corneal epithelium defect	50.76	14.86	14	15361	705	79728308
Toxicity to various agents	47.15	14.86	183	15192	421357	79307656
Anterior chamber cell	46.91	14.86	14	15361	935	79728078
Drug dependence	46.76	14.86	48	15327	40721	79688292
Punctate keratitis	46.39	14.86	14	15361	972	79728041
Hyporesponsive to stimuli	43.33	14.86	16	15359	2072	79726941
Hypokinesia	43.14	14.86	33	15342	19027	79709986
Interstitial lung disease	42.30	14.86	77	15298	112523	79616490
Fatigue	41.96	14.86	72	15303	929655	78799358
Drug ineffective	39.99	14.86	94	15281	1080819	78648194
Joint swelling	38.69	14.86	5	15370	288641	79440372
Delirium	35.82	14.86	61	15314	84566	79644447
Rhabdomyolysis	35.57	14.86	68	15307	103063	79625950
Blood lactate dehydrogenase increased	34.27	14.86	40	15335	39130	79689883
Drug interaction	33.91	14.86	164	15211	415019	79313994
Liver disorder	33.06	14.86	54	15321	72363	79656650
Corneal oedema	33.02	14.86	14	15361	2606	79726407
Peripheral swelling	31.01	14.86	7	15368	269610	79459403
Gamma-glutamyltransferase increased	30.89	14.86	45	15330	54635	79674378
Hypersensitivity	29.78	14.86	7	15368	262232	79466781
Off label use	29.57	14.86	84	15291	907131	78821882
Application site injury	28.82	14.86	5	15370	25	79728988
Infusion related reaction	28.52	14.86	5	15370	230232	79498781
Decreased appetite	28.47	14.86	136	15239	342282	79386731
Drug intolerance	28.18	14.86	8	15367	264111	79464902
Rheumatoid arthritis	27.01	14.86	4	15371	208466	79520547
Purpura senile	26.99	14.86	8	15367	522	79728491
Tarsal tunnel syndrome	26.90	14.86	8	15367	528	79728485
Reduced facial expression	25.91	14.86	12	15363	2753	79726260
Hyponatraemic encephalopathy	25.76	14.86	7	15368	333	79728680
Product dose omission issue	25.49	14.86	8	15367	247529	79481484
Eye haematoma	25.36	14.86	6	15369	162	79728851
Bradykinesia	25.27	14.86	17	15358	8026	79720987
Abnormal behaviour	25.11	14.86	33	15342	36388	79692625
Intentional product misuse	24.88	14.86	56	15319	95109	79633904
Drug eruption	24.58	14.86	36	15339	43899	79685114
Pain	24.53	14.86	63	15312	703739	79025274
Speech disorder	24.04	14.86	40	15335	54405	79674608
Suicidal ideation	23.50	14.86	48	15327	76292	79652721
Confusional state	23.38	14.86	122	15253	317875	79411138
Delusion	23.33	14.86	24	15351	20399	79708614
Arthralgia	23.31	14.86	47	15328	571756	79157257
Aspartate aminotransferase increased	23.22	14.86	69	15306	138572	79590441
Hyperventilation	23.16	14.86	16	15359	7883	79721130
Hypothermia	22.91	14.86	25	15350	22721	79706292
Treatment failure	22.72	14.86	3	15372	170483	79558530
Miosis	22.61	14.86	21	15354	15768	79713245
Swelling	22.32	14.86	7	15368	216704	79512309
Electrocardiogram QT prolonged	22.31	14.86	52	15323	90334	79638679
Activation syndrome	22.22	14.86	6	15369	279	79728734
Cerebral infarction	22.12	14.86	35	15340	45641	79683372
Heat illness	22.11	14.86	7	15368	570	79728443
Blood alkaline phosphatase increased	21.97	14.86	42	15333	63622	79665391
Application site ulcer	21.47	14.86	5	15370	126	79728887
Lymphocyte stimulation test positive	21.03	14.86	8	15367	1125	79727888
Alanine aminotransferase increased	20.12	14.86	73	15302	162497	79566516
Dissociative disorder	19.68	14.86	7	15368	814	79728199
Arthropathy	19.57	14.86	5	15370	177106	79551907
Labelled drug-drug interaction issue	19.31	14.86	8	15367	1405	79727608
Restlessness	18.99	14.86	33	15342	46459	79682554
Resorption bone increased	18.98	14.86	8	15367	1467	79727546
Fall	18.70	14.86	159	15216	487470	79241543
Pain in extremity	18.49	14.86	26	15349	364512	79364501
Alopecia	18.24	14.86	11	15364	231344	79497669
Vestibular disorder	17.98	14.86	9	15366	2446	79726567
Cough	17.78	14.86	27	15348	366762	79362251
Mental impairment	17.59	14.86	20	15355	19016	79709997
Hypoglycaemic coma	17.24	14.86	11	15364	4749	79724264
Dysarthria	16.79	14.86	39	15336	67583	79661430
Intellectual disability	16.46	14.86	7	15368	1313	79727700
Postoperative delirium	16.42	14.86	5	15370	358	79728655
Blood pressure decreased	16.17	14.86	49	15326	99417	79629596
Pneumonia aspiration	15.95	14.86	38	15337	66929	79662084
Torsade de pointes	15.70	14.86	19	15356	19293	79709720
Lower respiratory tract infection	15.58	14.86	3	15372	129217	79599796
Attention deficit hyperactivity disorder	15.46	14.86	9	15366	3300	79725713
Ventricular extrasystoles	15.39	14.86	19	15356	19685	79709328
Dependence	15.20	14.86	8	15367	2414	79726599
Haemodialysis	14.97	14.86	18	15357	18150	79710863

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05CD05	NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Benzodiazepine derivatives
FDA CS	M0002356	Benzodiazepines
MeSH PA	D000759	Adjuvants, Anesthesia
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D018682	GABA Agents
MeSH PA	D018757	GABA Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
FDA EPC	N0000175694	Benzodiazepine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Insomnia	indication	193462001
Suicidal thoughts	contraindication	6471006
Alcohol intoxication	contraindication	25702006
Depressive disorder	contraindication	35489007
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Sleep apnea	contraindication	73430006	DOID:0050847
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Hypoalbuminemia	contraindication	119247004
Disease of liver	contraindication	235856003	DOID:409
Sleep automatism	contraindication	247962006
Syncope	contraindication	271594007
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.22	Basic
pKa2	4.62	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
GABA A receptor alpha-5/beta-2/gamma-3	Ion channel	P31644 P47870 Q99928	GBRA5_HUMAN GBRB2_HUMAN GBRG3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.70	WOMBAT-PK	CHEMBL
GABA A receptor alpha-3/beta-2/gamma-2	Ion channel	P18507 P34903 P47870	GBRG2_HUMAN GBRA3_HUMAN GBRB2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.88	WOMBAT-PK	CHEMBL
GABA A receptor alpha-3/beta-2/gamma-3	Ion channel	P34903 P47870 Q99928	GBRA3_HUMAN GBRB2_HUMAN GBRG3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.11	WOMBAT-PK	CHEMBL
GABA A receptor alpha-5/beta-3/gamma-3	Ion channel	P28472 P31644 Q99928	GBRB3_HUMAN GBRA5_HUMAN GBRG3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.70	WOMBAT-PK	CHEMBL
GABA A receptor alpha-5/beta-2/gamma-2	Ion channel	P18507 P31644 P47870	GBRG2_HUMAN GBRA5_HUMAN GBRB2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	9.22	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-2	Ion channel	P14867 P18507 P47870	GBRA1_HUMAN GBRG2_HUMAN GBRB2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	9.16	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-2/beta-3/gamma-2	Ion channel	P18507 P28472 P47869	GBRG2_HUMAN GBRB3_HUMAN GBRA2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	9.23	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-3/beta-3/gamma-2	Ion channel	P18507 P28472 P34903	GBRG2_HUMAN GBRB3_HUMAN GBRA3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.85	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-5/beta-3/gamma-2	Ion channel	P18507 P28472 P31644	GBRG2_HUMAN GBRB3_HUMAN GBRA5_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	9.02	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-3	Ion channel	P14867 P47870 Q99928	GBRA1_HUMAN GBRB2_HUMAN GBRG3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.64	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-1/beta-3/gamma-2	Ion channel	P14867 P18507 P28472	GBRA1_HUMAN GBRG2_HUMAN GBRB3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	9.10	WOMBAT-PK	CHEMBL
GABA-A receptor	Ion channel	O14764 P14867 P18505 P18507 P28472 P31644 P34903 P47869 P47870 P48169 Q16445 Q8N1C3 Q99928	GBRD_HUMAN GBRA1_HUMAN GBRB1_HUMAN GBRG2_HUMAN GBRB3_HUMAN GBRA5_HUMAN GBRA3_HUMAN GBRA2_HUMAN GBRB2_HUMAN GBRA4_HUMAN GBRA6_HUMAN GBRG1_HUMAN GBRG3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	9.10	IUPHAR	CHEMBL
Platelet-activating factor receptor	GPCR	P25105	PTAFR_HUMAN		Ki	5.88	PDSP
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		Ki	4.27	WOMBAT-PK
Cholecystokinin receptor type A	GPCR		CCKAR_RAT		IC50	4.41	CHEMBL
GABA-A receptor; anion channel	Ion channel		GBRP_RAT GBRB1_RAT GBRD_RAT GBRG2_RAT GBRA5_RAT GBRA3_RAT GBRG1_RAT GBRA2_RAT GBRA4_RAT GBRG3_RAT GBRA6_RAT GBRA1_RAT GBRB3_RAT GBRB2_RAT Q91ZM7_RAT GBRE_RAT		Ki	9.10	CHEMBL

External reference:

ID	Source
4018066	VUID
N0000146407	NUI
D00387	KEGG_DRUG
4018066	VANDF
C0040879	UMLSCUI
CHEMBL646	ChEMBL_ID
DB00897	DRUGBANK_ID
D014229	MESH_DESCRIPTOR_UI
5556	PUBCHEM_CID
7313	IUPHAR_LIGAND_ID
3409	INN_ID
1HM943223R	UNII
10767	RXNORM
3103	MMSL
5618	MMSL
d00397	MMSL
001466	NDDF
111128007	SNOMEDCT_US
386984001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Halcion	HUMAN PRESCRIPTION DRUG LABEL	1	0009-0017	TABLET	0.25 mg	ORAL	NDA	33 sections
Halcion	HUMAN PRESCRIPTION DRUG LABEL	1	0009-0017	TABLET	0.25 mg	ORAL	NDA	33 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4858	TABLET	0.13 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4858	TABLET	0.13 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4859	TABLET	0.25 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4859	TABLET	0.25 mg	ORAL	ANDA	30 sections
TRIAZOLAM	HUMAN PRESCRIPTION DRUG LABEL	1	16590-236	TABLET	0.25 mg	ORAL	NDA authorized generic	28 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	21695-284	TABLET	0.25 mg	ORAL	ANDA	22 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	21695-303	TABLET	0.13 mg	ORAL	ANDA	22 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	43063-996	TABLET	0.25 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	43063-996	TABLET	0.25 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	43063-996	TABLET	0.25 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	43063-996	TABLET	0.25 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	43353-451	TABLET	0.25 mg	ORAL	NDA AUTHORIZED GENERIC	29 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0522	TABLET	0.25 mg	ORAL	NDA AUTHORIZED GENERIC	32 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4733	TABLET	0.25 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4733	TABLET	0.25 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	50090-6471	TABLET	0.25 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	50436-3718	TABLET	0.25 mg	ORAL	NDA AUTHORIZED GENERIC	28 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	50742-645	TABLET	0.13 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	50742-645	TABLET	0.13 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	50742-646	TABLET	0.25 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	50742-646	TABLET	0.25 mg	ORAL	ANDA	30 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	55289-787	TABLET	0.25 mg	ORAL	NDA authorized generic	33 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	55289-787	TABLET	0.25 mg	ORAL	NDA authorized generic	33 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	59762-3717	TABLET	0.13 mg	ORAL	NDA AUTHORIZED GENERIC	33 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	59762-3717	TABLET	0.13 mg	ORAL	NDA AUTHORIZED GENERIC	33 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	59762-3718	TABLET	0.25 mg	ORAL	NDA AUTHORIZED GENERIC	33 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	59762-3718	TABLET	0.25 mg	ORAL	NDA AUTHORIZED GENERIC	33 sections
Triazolam	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2956	TABLET	0.25 mg	ORAL	ANDA	30 sections